Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review

The New Profile of Drug-Resistant Tuberculosis in Russia: A Global and Local Perspective

Review

The New Profile of Drug-Resistant Tuberculosis in Russia: A Global and Local Perspective

Institute of Medicine (US) Forum on Drug Discovery, Development, and Translation et al.

Excerpt

The objectives of the workshop were to learn from the historical and contemporary experiences of the Russian public health community in its efforts to control and combat the spread of drug-resistant tuberculosis (TB), and to draw lessons regarding best practices and novel approaches that can be applied in the region and across the globe. An important objective of the presentations and discussions among workshop speakers and guests was to forge new linkages and collaborations across multiple disciplines and countries and facilitate the sharing of scientific knowledge to benefit TB control efforts. Specifically, the workshop was designed to:

  1. increase awareness and create a renewed sense of urgency with respect to the growing global burden of multidrug-resistant (MDR) and extensively drug-resistant (XDR) TB and its profile in Russia;

  2. consider the magnitude of transmission of drug-resistant strains and options for control of transmission and infection;

  3. address the MDR TB burden in vulnerable populations, including children, those coinfected with HIV, and substance abusers;

  4. assess current treatment options and approaches to patient care, taking into account the unique needs of the population being treated;

  5. discuss the supply of quality-assured second-line TB drugs and the pipeline for a new “cocktail” of TB drugs;

  6. assess the current state of the art for rapid detection of drug resistance and the implications for patient management; and

  7. suggest policies for accelerating improvements in treatment and infection control for drug-resistant TB.

PubMed Disclaimer

Grants and funding

This study was supported by Department of Health and Human Services (Contract Nos. N01-OD-4-2139 and 223001003T), the U.S. State Department (S-LMAQM-08-GR-071), the American Diabetes Association, the American Society for Microbiology, Amgen Inc., the Association of American Medical Colleges, Bristol-Myers Squibb, the Burroughs Wellcome Fund, Celtic Therapeutics, LLLP, the Critical Path Institute, the Doris Duke Charitable Foundation, Eli Lilly & Co., GlaxoSmithKline, Johnson & Johnson, Novartis Pharmaceuticals Corporation, and Pfizer, Inc.